|Biotech Due Diligence||
Infinity Pharma $INFI shares have been strong since the early 2012 failure of their pancreatic cancer trial with saridegib (IPI-926). However, they do not appear to have any market-moving data presentations at AACR or ASCO this year. See below for two studies to be presented at AACR.
Find below the abstracts being presented by Astex Pharma at AACR on their clinical stage drugs SGI-110 (follow-on to DACOGEN aka decitabine) and AT13148, an AGC kinase inhibitor.
Also, visit HSP90 Central for details on AACR presentations related to ASTX's heat shock protein 90 inhibitor AT13387.
Astex Pharma will present a number of abstracts at next week's American Association for Cancer Research meeting. Among them may be a peak into the preclinical drug candidates next poised to enter the clinic in 2012. We may also get details at the March 27th Research and Development day. See the full abstracts below.
Next week on 3/29 Isis Pharma will once again present further long-term safety data for its lipid lowering drug candidate KYNAMRO (mipomersen) at the XVI INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS. See below for the full abstract.
For an extensive discussion on mipomersen safety and efficacy, see my prior report.
Isis Pharma is presenting two abstracts at the American College of Cardiology Scientific Sessions this weekend, related to two drugs in their cardiovascular franchise. See below for complete details.